Spanish pharmaceutical company Almirall and Belgian biotech Galapagos have entered into a three-year agreement “aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall.” According to the companies, the deal could be worth €7.5 million to Galapagos subsidiary BioFocus, which will be doing the research. Almirall’s respiratory pipeline currently includes several inhaled drugs, including aclidinium bromide, for which it has submitted an NDA in the US and and MAA in Europe.
Almirall CSO and Executive Director of R&D explained, “We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies,” and Galapagos Senior VP of Services and Managing Director of BioFocus responded, “We are delighted to form a drug discovery alliance with one of Europe’s leading research-based pharmaceutical companies.”
Read the Almirall press release.
